Marshall Wace LLP Raises Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Marshall Wace LLP increased its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 190.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 488,889 shares of the company's stock after purchasing an additional 320,472 shares during the period. Marshall Wace LLP owned 1.63% of Silence Therapeutics worth $3,364,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock worth $42,000 after purchasing an additional 5,233 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Silence Therapeutics in the 4th quarter worth $120,000. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics during the 4th quarter worth $69,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Silence Therapeutics during the 4th quarter valued at about $134,000. Finally, JPMorgan Chase & Co. purchased a new stake in Silence Therapeutics in the fourth quarter valued at about $26,000. Hedge funds and other institutional investors own 98.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SLN. The Goldman Sachs Group decreased their price target on shares of Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 7th. BMO Capital Markets reduced their price target on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Finally, Morgan Stanley reduced their price target on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

Silence Therapeutics Price Performance

Shares of SLN traded up $0.24 during midday trading on Thursday, reaching $3.94. The stock had a trading volume of 84,623 shares, compared to its average volume of 294,695. The company's fifty day simple moving average is $3.50 and its two-hundred day simple moving average is $7.27. The company has a market cap of $117.77 million, a price-to-earnings ratio of -2.50 and a beta of 1.25. Silence Therapeutics plc has a 1-year low of $1.97 and a 1-year high of $24.38.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.